EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease

Rachel Nice, Simeng Lin iD, Neil Chanchlani iD, Claire Bewshea iD, Nicholas A Kennedy, Tariq Ahmad iD, Paul G Winyard, James Goodhand, Timothy J McDonald iD

The Journal of Applied Laboratory Medicine · 2025

DOI: 10.1093/jalm/jfaf149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2025. Verfasst von Rachel Nice und 8 weiteren Autor:innen. Beteiligte Einrichtung: Blood Sciences Academic Department, Royal Devon University Healthcare Trust, Exeter, United Kingdom. Hauptthemen laut MEDLINE: Crohn Disease, Adalimumab, Infliximab, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal Devon and Exeter NHS Foundation Trust, Guts UK, Crohn's and Colitis UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We sought to determine the prevalence, clinical impact, neutralizing capacity, and cross-reactivity of pre-existing antibodies to infliximab and adalimumab in antitumor necrosis factor (TNF) treatment-naïve patients with active luminal crohn disease.

Methods

The prevalence of antibodies to infliximab and adalimumab at entry to the “Personalised Anti-TNF Therapy in Crohn's Disease Study” (PANTS) were measured using the drug-tolerant IDKmonitor Total antidrug antibody ELISAs. Neutralizing capacity in positive cases was determined using iLite™ cell-based assays.

Results

Pre-existing antibodies to infliximab were more common (6.3%, 96/1525 vs 2.4%, 36/1525, P < 0.01) and detectable at higher concentrations [median (IQR) 23.9 (14.2–55.2) AU/mL vs 7.2 (6.3–10.4) AU/mL, P < 0.0001] to infliximab than adalimumab. A few patients [1.3% (95% CI 0.6–1.8) 20/1525] had antidrug antibody reactivity to both drugs. None of the detected antidrug antibodies had demonstrable anti-TNF neutralizing capacity. No associations were seen between pre-existing antibody positivity, adverse drug reactions, drug levels, or response status at weeks 14 or 54 or subsequent immunogenicity. Cross-reactivity with rheumatoid factor and antimouse antibodies was detected (>10 IU/mL) in 6.6% (95% CI 3.2–13.0) (7/106) and 17.0% (95% CI 10.5–25.2) (19/112) of patients with pre-existing antibodies.

Conclusions

Pre-existing antidrug antibodies are common but do not neutralize anti-TNF drug activity in vitro, promote drug clearance, or influence clinical response to anti-TNF drugs. Further work is required to understand this cross-reactivity and to determine the exact nature of the antibodies detected in drug-naïve individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAdalimumabInfliximabTumor Necrosis Factor-alphaAntibodies, NeutralizingTumor Necrosis Factor InhibitorsHumansMaleFemaleAdultTreatment FailureCross ReactionsMiddle Aged

Substanzen

AdalimumabInfliximabTumor Necrosis Factor-alphaAntibodies, NeutralizingTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Blood Sciences Academic Department, Royal Devon University Healthcare Trust, Exeter, United Kingdom.
  • Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, United Kingdom.
  • Department of Gastroenterology, Royal Devon University Healthcare Trust, Exeter, United Kingdom.
  • Inflammation Research Group, University of Exeter Medical School, Exeter, United Kingdom.

ORCID-Profile: Simeng Lin, Neil Chanchlani, Claire Bewshea, Tariq Ahmad, Timothy J McDonald

Förderung

  • Royal Devon and Exeter NHS Foundation Trust
  • Guts UK
  • Crohn's and Colitis UK
  • Cure crohn's's Colitis
  • AbbVie
  • Merck Sharp and Dohme
  • NAPP Pharmaceuticals Ltd UK
  • Pfizer Ltd US

Zitieren

APA

Nice, R., Lin, S., Chanchlani, N., Bewshea, C., Kennedy, N. A., Ahmad, T., Winyard, P. G., Goodhand, J., & McDonald, T. J. (2025). Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfaf149

Vancouver

Nice R, Lin S, Chanchlani N, Bewshea C, Kennedy NA, Ahmad T, et al. Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease. The Journal of Applied Laboratory Medicine. 2025. doi:10.1093/jalm/jfaf149

BibTeX
@article{Nice2025,
  author = {Nice, Rachel and Lin, Simeng and Chanchlani, Neil and Bewshea, Claire and Kennedy, Nicholas A and Ahmad, Tariq and Winyard, Paul G and Goodhand, James and McDonald, Timothy J},
  title = {Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2025},
  doi = {10.1093/jalm/jfaf149}
}
Kostenlos starten →